U.S. Advocate Of Drug Quality Issues Says India DCGI Viewed As Corrupt
This article was originally published in PharmAsia News
A U.S. advocate of a stern approach toward drugs imported from India suggested the nation's drug regulator himself is part of the problem and "is seen as corrupt" by American physicians and patients.
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.